Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Epic American Credit and Bond Bubble Laboratory -- Ignore unavailable to you. Want to Upgrade?

To: NOW who wrote (44831)	11/5/2005 10:01:14 PM
From: Elroy Jetson	Read Replies (1) \| Respond to of 110194

Materials don't have to be brought from India to Thailand. -- India, like Italy and Taiwan, do not register or protect foreign drug patents. This situation has made India based Cipla a pharmaceutical powerhouse which produces drugs, currently under patent, at a typically 99% discount from the original manufacturer. Although the drugs can only be sold or brought into nations which also do not protect foreign drug patents, Cipla has been a godsend for nations like Thailand with a high rate of HIV infection. Taiwan pharma companies have gone to the trouble of requesting a license to make Tamiflu from Roche - a request in which Cipla has joined. This request can only mean one of several things: a.) Tamiflu is too complex to make without either years of experimentation or bench notes from Roche; b.) They would like to sell Tamiflu in nations which protect foreign drug patents. Roche may be concerned about the transfer of technology to Cipla and Taiwanese pharma companies, which could then be used to knock off additional drugs. .